Taurine 10 pp 831-841 | Cite as

Taurine Reverses Atrial Structural Remodeling in Ach-Cacl2 Induced Atrial Fibrillation Rats

  • Qunhui Yang
  • Gaofeng Wu
  • Limei Han
  • Ying Feng
  • Shumei Lin
  • Qiufeng Lv
  • Jiancheng Yang
  • Jianmin HuEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 975)


Taurine has been reported to have anti-arrhythmia effects, but the anti-atrial fibrillation (AF) effects and its mechanism remain incompletely understood. In the present study, the therapy effects and partly mechanisms were investigated. AF animal model was established by intravenous administered with the mixture of acetylcholine (Ach) and CaCl2 (66 μg/mL + 10 mg/mL) (i.v.) for 7 days. The actions of taurine (99 mg/kg∙d, introgastric administration) on the levels of Hs-CRP, IL-6, TNF-α, MMP-9, AngII, the extent of the fibrosis and ultrastructural changes in left atrial were studied. The data showed that the serum levels of TNF-α, IL-6, AngII and the plasma levels of Hs-CRP and MMP-9 were significantly elevated in automatic recovery group relative to the control group (p < 0.01), which were all decreased by taurine administration (p < 0.01) similar to Verapamil treatment. Masson’s trichrome staining of the left atrial tissue showed an obvious interstitial fibrosis in rats of automatic recovery group. The alteration could be reversed by additional taurine. Electron microscopy revealed that taurine administration could significantly alleviate the ultrastructural damage of atrial cells, and the effects were similar to the Verapamil treatment. In conclusion, the results suggested that taurine could inhibit the structural remodeling of AF in rats partly by decreasing the levels of inflammatory factors and profibrotic molecules, attenuating the extent of myocardial fibrosis and protecting the integrity of myocardial ultrastructure.


Taurine Atrial fibrillation Inflammatory factors Fibrosis Ultrastructure 





Atrial fibrillation


Angiotensin II


High-sensitive C-reactive protein




Matrix metallaproteinase-9


Matrix metalloproteinases


Tumor necrosis factor-α



This research was supported by grants from the National Natural Science Foundation (No. 31502026, No. 31302051, No. 31402160) of China and Cultivation Plan for Youth Agricultural Science and Technology Innovative Talents of Liaoning Province (No. 2014049).


  1. Allessie M, Ausma J, Schotten U (2002) Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54:230–246CrossRefPubMedGoogle Scholar
  2. Balasubramanian S, Fan M, Messmer-Blust AF, Yang CH, Trendel JA, Jeyaratnam JA, Pfeffer LM, Vestal DJ (2011) The interferon-γ-induced GTPase, mGBP-2, inhibits TNF-α induction of matrix metalloproteinase-9 (MMP-9) by inhibiting NF-κB and Rac. J Biol Chem 286:20054–20064CrossRefPubMedPubMedCentralGoogle Scholar
  3. Burstein B, Nattel S (2008) Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 51:802–809CrossRefPubMedGoogle Scholar
  4. Chazov EI, Malchikova LS, Lipina NV, Asafov GB, Smirnov VN (1974) Taurine and electrical activity of the heart. Circ Res 35(Suppl. 3):11–21PubMedGoogle Scholar
  5. Chen CL, Huang SK, Lin JL, Lai LP, Lai SC, Liu CW, Chen WC, Wen CH, Lin CS (2008) Upregulation of matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases in rapid atrial pacing-induced atrial fibrillation. J Mol Cell Cardiol 45(6):742–753CrossRefPubMedGoogle Scholar
  6. Chen CL, Gong TT, Tang YQ, Kou YY, Yu P, Shao R, Zhang CF (2009) Establishment of atrial fibrillation model in SD rats. Lab Anim Sci 26(3):1–4Google Scholar
  7. Chou CH, Chang YY, Tzang BS, Hsu CL, Lin YL, Lin HW, Chen YC (2012) Effects of taurine on hepatic lipid metabolism and anti-inflammation in chronic alcohol-fed rats. J Food Chem 135:24–30CrossRefGoogle Scholar
  8. Eby G, Halcomb WW (2006) Elimination of cardiac arrhythmias using oral taurine with l-arginine with case histories: hypothesis for nitric oxide stabilization of the sinus node. Med Hypotheses 67(5):1200–1204CrossRefPubMedGoogle Scholar
  9. Fernandes JC, Martel-Pelletier J, Pelletier JP (2002) The role of cytokines in osteoarthritis pathophysiology. Biorheology 39(1–2):237–246PubMedGoogle Scholar
  10. Friedrichs K, Klinke A, Baldus S (2011) Inflammatory pathways underlying atrial fibrillation. Trends Mol Med 17(10):556–563CrossRefPubMedGoogle Scholar
  11. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–2375CrossRefPubMedGoogle Scholar
  12. Gu J, Hu W, Liu X (2014) Pioglitazone improves potassium channel remodeling induced by angiotensin II in atrial myocytes. Med Sci Monit Basic Res 20:153–160PubMedPubMedCentralGoogle Scholar
  13. Henningsen KM, Therkelsen SK, Bruunsgaard H, Krabbe KS, Pedersen BK, Svendsen JH (2009) Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion. Scand J Clin Lab Invest 69(3):425–432CrossRefPubMedGoogle Scholar
  14. Issac TT, Dokainish H, Lakkis NM (2007) Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol 50:2021–2028CrossRefPubMedGoogle Scholar
  15. Ito T, Kimura Y, Uozumi Y, Takai M, Muraoka S, Matsuda T, Ueki K, Yoshiyama M, Ikawa M, Okabe M, Schaffer SW, Fujio Y, Azuma J (2008) Taurine depletion caused by knocking out the taurine transporter gene leads to cardiomyopathy with cardiac atrophy. J Mol Cell Cardiol 44:927–937Google Scholar
  16. Jia L, Li Y, Xiao C, Du J (2012) Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci 17:221–231CrossRefGoogle Scholar
  17. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J (2002) Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 54:361–379CrossRefPubMedGoogle Scholar
  18. Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J (2009) Current concepts in the pathogenesis of atrial fibrillation. Am Heart J 157:243–252CrossRefPubMedGoogle Scholar
  19. Latchoumycandane C, Nagy LE, McIntyre TM (2014) Chronic ethanol ingestion induces oxidative kidney injury through taurine-inhibitable inflammation. J Free Radic Biol Med 69:403–416CrossRefGoogle Scholar
  20. Learn DB, Fried VA, Thomas EL (1996) Taurine and hypotaurine contents of human leukocytes. J Leukoc Biol 48:174–182Google Scholar
  21. Lombardini JB (1996) Taurine depletion in the intact animal stimulates in vitro phosphorylation of a ~44-kDa protein present in the mitochondrial fraction of the rat heart. J Mol Cell Cardiol 28:1957–1961CrossRefPubMedGoogle Scholar
  22. Marcus GM, Smith LM, Ordovas K, Scheinman MM, Kim AM, Badhwar N, Lee RJ, Tseng ZH, Lee BK, Olgin JE (2010) Intracardiac and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm 7(2):149–154CrossRefPubMedGoogle Scholar
  23. McCarty MF (2010) Practical prevention of cardiac remodeling and atrial fibrillation with full-spectrum antioxidant therapy and ancillary strategies. Med Hypotheses 75(2):141–147CrossRefPubMedGoogle Scholar
  24. Pamukcu B, Lip GY (2011) Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. Expert Opin Pharmacother 12:131–140CrossRefPubMedGoogle Scholar
  25. Patel P, Dokainish H, Tsai P, Lakkis N (2010) Update on the association of inflammation and atrial fibrillation. J Cardiovasc Electrophysiol 21:1064–1070CrossRefPubMedGoogle Scholar
  26. Read WO, Welty JD (1963) Effect of taurine on epinephrine and digoxin induced irregularities of the dog heart. J Pharmacol Exp Ther 139:283–289PubMedGoogle Scholar
  27. Saba S, Janczewski AM, Baker LC, Shusterman V, Gursoy EC, Feldman AM, Salama G, McTiernan CF, London B (2005) Atrial contractile dysfunction, fibrosis, and arrhythmias in a mouse model of cardiomyopathy secondary to cardiac-specific overexpression of tumor necrosis factor-α. Am J Physiol Heart Circ Physiol 289(4):H1456–H1467CrossRefPubMedGoogle Scholar
  28. Schuller-Levis G, Gordon RE, Wang C, Park SY, Park E (2009) Protection of bleomycin-induced fibrosis and inflammation by taurine. Int Immunopharmacol 9(7–8):971–977CrossRefPubMedGoogle Scholar
  29. Wu GF, Matsuwaki T, Tanaka Y, Yamanouchi K, Hu JM, Nishihara M (2013) Taurine counteracts the suppressive effect of lipopolysaccharide on neurogenesis in the hippocampus of rats. Adv Exp Med Biol 775:111–119CrossRefPubMedGoogle Scholar
  30. Xu YJ, Arneja AS, Tappia PS, Dhalla NS (2008) The potential health benefits of taurine in cardiovascular disease. Exp Clin Cardiol 13(2):57–65PubMedPubMedCentralGoogle Scholar
  31. Zhao L, Lou JS, Kang Y (2013) Taurine-magnesium coordination compound attenuates hypoxia/reoxygenation induced ion channel dysfunction in rat ventricular myocytes. Drug Res (Stuttg) 63(4):185–191CrossRefGoogle Scholar
  32. Zheng LH, Sun W, Yao Y, Hou BB, Qiao Y, Zhang S (2016) Associations of big endothelin-1 and C-reactive protein in atrial fibrillation. J Geriatr Cardiol 13(5):465–470PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2017

Authors and Affiliations

  • Qunhui Yang
    • 1
  • Gaofeng Wu
    • 1
  • Limei Han
    • 1
  • Ying Feng
    • 1
  • Shumei Lin
    • 1
  • Qiufeng Lv
    • 1
  • Jiancheng Yang
    • 1
  • Jianmin Hu
    • 1
    Email author
  1. 1.Liaoning Provincial Key Laboratory of Zoonosis, College of Animal Science and Veterinary MedicineShenyang Agricultural UniversityShenyangPeople’s Republic of China

Personalised recommendations